The CNS Drug model
CNS & Neurological Disorders - Drug Targets
... developing CNS manifestations remain matters of open ...animal model studies are warranted to understand the pathogenic linkages between aPLs and the neurologic symptoms observed in patients with ...
13
CNS & Neurological Disorders - Drug Targets
... Amyloid aggregation is usually initiated from the conversion of monomer form. Generally, amyloid monomers undergo conformational changes, followed by further misfolding and aggregating to form a small oligomer, ...
9
Zebrafish models in neuropsychopharmacology and CNS drug discovery
... the model, it is necessary to evaluate its face and construct ...the model resembles the disease in question, while construct validity determines whether the model measures what it has set out to ...
20
Considerations for Target Selection in CNS Drug Discovery Programs
... oral drug-like chemical ...oral, drug- like physicochemical ...mathematical model that uses structural information about a target’s binding site in order to estimate a maximal achievable affinity for ...
6
Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics
... of drug development, physicochemical properties of drugs can be measured in vitro and/or predicted by in silico ...chemical drug properties can inform the CNS PBPK model to predict neuro-PK of ...
13
Preclinical assessment of CNS drug action using eye movements in mice
... The drug development process for CNS indications is hampered by a paucity of preclinical tests that accurately predict drug efficacy in ...of CNS-active drugs induce characteris- tic ...
Systems pharmacokinetic models to the prediction of local CNS drug concentrations in human
... developed model consisted of plasma and main CNS physiological compartments (brain ECF , brain ICF , and four different CSF sites) that could adequately describe the rat PK data of these nine structurally ...
222
Preclinical assessment of CNS drug action using eye movements in mice
... The drug development process for CNS indications is hampered by a paucity of preclinical tests that accurately predict drug efficacy in ...of CNS-active drugs induce characteris- tic ...
15
Benzodiazepines: A Model for Central Nervous System (CNS) Depressants
... • Original strategy: taper at a rate of 1mg q 3 days; however, many individuals taking the drug for longer than 12 weeks could not tolerate this strategy • More currently, taper at rate of 0.5mg q 3 days; this ...
34
Tubulin and microtubules as drug targets for potential cancer chemotherapy and CNS-directed therapies
... mouse model of Charcot-Marie-Tooth disease, a descrease in acetylated tubulin levels and the axonal transport defects observed in these mice were corrected by the administration of HDAC6 inhibitors that also ...
277
Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics
... Interestingly, when comparing microsomes of humans versus these two species, the human cocaine metabolism showed a closer resemblance to the mice cocaine metabolism, indicat- ing that the mouse is a better animal ...
13
CNS Drug Disposition: The Relationship Between In Situ Brain Permeability and Brain Free Fraction
... the CNS, whereas the sink action of tissue binding becomes important for more lipophilic drug ...cell model in conjunction with brain tissue binding and brain permeability across the BBB appears to ...
45
Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse
... the CNS in close proximity to neu- rons [52] are likely to be exposed to dopamine during spillover from the releasing synapse into the extrasynap- tic space ...measured drug-induced dopamine flux to be as ...
14
CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis
... the CNS by p-glycoprotein ...the CNS may be a way to maximize the therapeutic effect, while reducing side effects from the increased blood concentrations required to achieve adequate CNS ...the ...
13
CNS ACTIVITY OF THE METHANOL EXTRACTS OF HEARTWOOD OF TECOMA STANS IN EXPERIMETAL ANIMAL MODEL
... reference drug benzodiazipine, which acts as a anxiolytics (at low doses), anticonvulsants, and also produce sedation and a myorelaxant effect at higher doses 12 ...other CNS depressant ...
10
Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease
... pharmacokinetic model allowed the integration of the kinetics of L-DOPA and its conversion to DOPAC and HVA in both control and rotenone-treated responder ...
14
Recent Developments in the CNS Drug Market
... the CNS Drug Market Description: This report reviews the global market for CNS prescription drugs and recent developments within the marketplace, including collaborative agreements, recent clinical ...
6
CNS Anticancer Drug Discovery and Development Conference
... 8:40am Therapy for Gliomas and Medulloblastoma: Reflection on a Life’s Work in Experimental Therapeutics and Drug Discovery/Development Victor A. Levin, MD University of California, San Francisco; Emeritus ...
8
The brain slice method for studying drug distribution in the CNS
... total drug concentration in the brain and the concentration of unbound drug in the brain interstitial fluid, regardless of blood – brain barrier ...of drug distribution in the brain because the ...
9
Approaches to CNS drug delivery with a focus on transporter mediated transcytosis
... Keywords: CNS-targeted drug delivery; Blood-brain barrier; Receptor-mediated transcytosis; Transient BBB disruption; Efflux-pump inhibition; Ring-opening metathesis polymerization ...their ...
43